ユナイテッド・イミュニティ株式会社
Founded 2017 · 17 employees on LinkedIn · 2 known investors
United Immunity develops a myeloid targeting platform using nanoparticles derived from pullulan polysaccharide to deliver therapeutics and vaccines to specific immune cells such as macrophages and dendritic cells. The platform targets applications in cancer immunotherapy and vaccine development by exploiting DC-SIGN receptor selectivity on myeloid cells.
Investors · 2
.png){kind=logo}
Frequently asked questions
- What does ユナイテッド・イミュニティ株式会社 do?
- United Immunity develops a myeloid targeting platform using nanoparticles derived from pullulan polysaccharide to deliver therapeutics and vaccines to specific immune cells such as macrophages and dendritic cells. The platform targets applications in cancer immunotherapy and vaccine development by exploiting DC-SIGN receptor selectivity on myeloid cells.
- Who are ユナイテッド・イミュニティ株式会社's investors?
- ユナイテッド・イミュニティ株式会社's investors include Nippon Venture Capital, Aozora Corporate Investment.